179250-25-0 Usage
General Description
TERT-BUTYL 4-(2-CYANOPHENYL)PIPERAZINE-1-CARBOXYLATE is a chemical compound with the molecular formula C19H26N4O2. It is a piperazine derivative with a tert-butyl group attached to the piperazine ring and a cyanophenyl group attached to the carbon atom. TERT-BUTYL 4-(2-CYANOPHENYL)PIPERAZINE-1-CARBOXYLATE is commonly used in pharmaceutical research and development as a building block for the synthesis of various biologically active molecules. It has potential therapeutic applications for the treatment of various diseases and conditions, and its chemical structure makes it a valuable component in medicinal chemistry. Additionally, it is important to handle and use this chemical with proper safety precautions and under the guidance of trained professionals due to its potential health hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 179250-25-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,2,5 and 0 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 179250-25:
(8*1)+(7*7)+(6*9)+(5*2)+(4*5)+(3*0)+(2*2)+(1*5)=150
150 % 10 = 0
So 179250-25-0 is a valid CAS Registry Number.
179250-25-0Relevant articles and documents
A class of GPR40 agonist compounds with amide structure, and uses thereof
-
Paragraph 0145; 0146; 0147; 0148; 0150, (2019/05/02)
The present invention relates to a class of amide compounds with a novel structure, and a pharmaceutical composition thereof, wherein the structure of the amide compound is represented by a general formula (I). According to the present invention, the amide compound (I) can regulate GPR40 activity, and can be used for GPR40 activity related diseases such as diabetes and metabolic syndrome. The formula I is defined in the specification.
TRICYCLIC COMPOUNDS
-
Paragraph 00374, (2017/08/01)
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers or congenital diseases. Specific cancers and congenital disease includes those that are mediated by YAP/TAZ.
CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
-
Paragraph 1602, (2016/02/21)
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
